Display options
Cite
Chbili C, Hassine A, Laouani A, et al. The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients. Arch Med Sci. 2016;13(2):353-360doi: 10.5114/aoms.2016.60090.
Chbili, C., Hassine, A., Laouani, A., Amor, S. B., Nouira, M., Ammou, S. B., & Saguem, S. (2017). The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients. Archives of medical science : AMS, 13(2), 353-360. https://doi.org/10.5114/aoms.2016.60090
Chbili, Chahra, et al. "The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients." Archives of medical science : AMS vol. 13,2 (2017): 353-360. doi: https://doi.org/10.5114/aoms.2016.60090
Chbili C, Hassine A, Laouani A, Amor SB, Nouira M, Ammou SB, Saguem S. The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients. Arch Med Sci. 2017 Mar 01;13(2):353-360. doi: 10.5114/aoms.2016.60090. Epub 2016 May 20. PMID: 28261288; PMCID: PMC5332445.
Copy Download .nbib Format: NLM
Share it on

Arch Med Sci. 2017 Mar 01;13(2):353-360. doi: 10.5114/aoms.2016.60090. Epub 2016 May 20.

The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients.

Archives of medical science : AMS

Chahra Chbili, Anis Hassine, Aicha Laouani, Sana Ben Amor, Manel Nouira, Sofiène Ben Ammou, Saad Saguem

Affiliations

  1. Metabolic Biophysics, Professional and Applied Toxicology Environmental Laboratory, Department of Biophysics, Faculty of Medicine Sousse, Sousse University, Sousse, Tunisia.
  2. Neurology Department of Central Hospital University (CHU), Sousse University, Sousse, Tunisia.

PMID: 28261288 PMCID: PMC5332445 DOI: 10.5114/aoms.2016.60090

Abstract

INTRODUCTION: The prescribed dose and carbamazepine plasma concentration to achieve the optimal therapeutic efficacy are highly variable from one patient to the other. Our study aimed to determine whether biological parameters may be used as plasma markers that can individually adjust the carbamazepine dose necessary to optimize therapeutic efficacy.

MATERIAL AND METHODS: Ninety-four epileptic patients under carbamazepine monotherapy and who have never used combination therapy were recruited from the consecutive admissions at the Department of Neurology "CHU Sahloul" of Sousse Central Hospital in Tunisia from February 2010 to April 2011. The patients were monitored for epilepsy for three years on average. Carbamazepine and 10,11-epoxide-carbamazepine concentrations were analyzed through high-performance liquid chromatography. Simultaneously, therapeutic efficacy was assessed through the annual number of seizures in each patient.

RESULTS: Our results showed the absence of any significant correlations between specific dose (mg/kg/day), carbamazepine plasma concentrations and therapeutic efficacy (

CONCLUSIONS: The results suggest that plasma levels of both carbamazepine and of 10,11-epoxide-carbamazepine must be set to achieve an optimum therapeutic response.

Keywords: 10; 11-epoxide-carbamazepine; carbamazepine; epileptic patients; number of seizures

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Bioorg Med Chem. 2012 Jan 15;20(2):775-83 - PubMed
  2. Epilepsy Res. 1994 Mar;17(3):257-69 - PubMed
  3. Arch Med Sci. 2013 Oct 31;9(5):858-64 - PubMed
  4. Lancet Neurol. 2011 May;10(5):446-56 - PubMed
  5. Pharmacogenomics. 2011 Jul;12(7):977-84 - PubMed
  6. Epilepsy Res. 2012 Feb;98(2-3):194-8 - PubMed
  7. Seizure. 2011 Jun;20(5):369-75 - PubMed
  8. Clin Pharmacol Ther. 1991 Jul;50(1):10-5 - PubMed
  9. Epilepsia. 2002 Apr;43(4):365-85 - PubMed
  10. Farm Hosp. 2011 Nov-Dec;35(6):326-39 - PubMed
  11. Pharmacogenomics. 2012 Jan;13(2):159-69 - PubMed
  12. Epilepsy Res. 2002 Nov;52(1):15-23 - PubMed
  13. Pharmacogenomics. 2006 Sep;7(6):831-41 - PubMed
  14. Clin Neuropharmacol. 2009 Jul-Aug;32(4):205-12 - PubMed
  15. Pharmacogenomics. 2005 Jun;6(4):357-71 - PubMed
  16. Pharmacogenetics. 2003 Oct;13(10):607-18 - PubMed
  17. Br J Clin Pharmacol. 1997 Jul;44(1):21-7 - PubMed
  18. Genomics. 1994 Sep 15;23(2):433-42 - PubMed
  19. Ann Biol Clin (Paris). 2014 Jul-Aug;72(4):453-9 - PubMed
  20. Eur J Clin Pharmacol. 2005 Mar;61(1):25-34 - PubMed
  21. Ann Neurol. 1994 Jun;35(6):743-6 - PubMed
  22. Drug Metab Dispos. 2005 Dec;33(12):1920-4 - PubMed
  23. Epilepsia. 1999;40 Suppl 10:S71-6 - PubMed
  24. Epilepsia. 2014 Aug;55(8):1301-6 - PubMed
  25. Ther Drug Monit. 1998 Dec;20(6):652-7 - PubMed
  26. Epilepsia. 1999 Aug;40(8):1141-6 - PubMed
  27. Arch Biochem Biophys. 1997 Jan 15;337(2):275-83 - PubMed
  28. J Pharmacol Exp Ther. 1996 Sep;278(3):1018-27 - PubMed
  29. J Psychopharmacol. 2010 Jul;24(7):1115-20 - PubMed
  30. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Dec 15;828(1-2):80-90 - PubMed
  31. Epilepsy Behav. 2002 Dec;3(6S1):18-23 - PubMed
  32. Br J Clin Pharmacol. 1976 Aug;3(4):575-82 - PubMed
  33. Epilepsia. 2010 Jun;51(6):1069-77 - PubMed
  34. Arch Med Res. 2004 Mar-Apr;35(2):168-71 - PubMed
  35. J Pharmacol Exp Ther. 1984 Nov;231(2):411-5 - PubMed
  36. Clin Chim Acta. 2011 Apr 11;412(9-10):755-60 - PubMed
  37. Seizure. 2006 Apr;15(3):156-64 - PubMed
  38. Eur J Clin Pharmacol. 2010 Jan;66(1):61-6 - PubMed
  39. J Clin Pharm Ther. 2012 Apr;37(2):153-6 - PubMed
  40. Pharmacogenomics. 2013 Jan;14 (1):35-45 - PubMed

Publication Types